~~<i id='D04DF6240A'><strike id='D04DF6240A'><tt id='D04DF6240A'><pre id='D04DF6240A'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

entertainment

author：Wikipedia 2025-10-01 22:49:41 - browse：8676

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Ozempic has benefits for kidney disease as well as diabetes

focus

Wikipedia

focus

explore

hotspot

LucasGuo,aboywitharareneurologicalconditioncalledZTTK,isencouragedbyhisfather,NathanGuo,andmother,Ad

WSS

Stem cell biologist probes earliest stages of human development

Families look for replacement for GSK asthma drug Flovent

Immune cells and nerve overgrowth may explain recurring UTI pain

Lack of health data on LGBTQ+ people has serious consequences

Microsoft's Peter Lee: Generative AI could help doctors be more human

Scientific mystery highlights the blind spots in genomics databases

focus

entertainment

focus

Medical records are filled with copy

Gut bacteria may contribute to kidney autoimmunity, study finds

How to save PrEP access — and even expand it

Streamlined flu vaccines recommended by FDA advisory panel

Apple is now the first public company to be valued at $3 trillion

Insurer loopholes limit power of law against surprise medical bills

United colonoscopy coverage change 'may cost lives,' doctors say

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

In Memoriam: Notable people who died in 2023

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

focus

Bird flu reported in person exposed to presumably infected cattle

Microsoft's Peter Lee: Generative AI could help doctors be more human

Insurer loopholes limit power of law against surprise medical bills

Scientific mystery highlights the blind spots in genomics databases

Longer MASH drug regimen improved liver, Akero study finds

Ancient Greek ideas underpin modern concepts of pregnancy

Wikipedia

focus

explore

hotspot